DK2742068T3 - Nye antistoffer mod phosphorylcholin - Google Patents

Nye antistoffer mod phosphorylcholin Download PDF

Info

Publication number
DK2742068T3
DK2742068T3 DK12747915.2T DK12747915T DK2742068T3 DK 2742068 T3 DK2742068 T3 DK 2742068T3 DK 12747915 T DK12747915 T DK 12747915T DK 2742068 T3 DK2742068 T3 DK 2742068T3
Authority
DK
Denmark
Prior art keywords
antibodies against
new antibodies
against phosphorylcholine
phosphorylcholine
new
Prior art date
Application number
DK12747915.2T
Other languages
Danish (da)
English (en)
Inventor
Knut Pettersson
Ola Camber
Dan Sexton
Andrew E Nixon
Original Assignee
Athera Biotechnologies Ab
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athera Biotechnologies Ab, Dyax Corp filed Critical Athera Biotechnologies Ab
Application granted granted Critical
Publication of DK2742068T3 publication Critical patent/DK2742068T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
DK12747915.2T 2011-08-09 2012-08-08 Nye antistoffer mod phosphorylcholin DK2742068T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161521593P 2011-08-09 2011-08-09
PCT/EP2012/065505 WO2013020995A1 (en) 2011-08-09 2012-08-08 New antibodies against phosphorylcholine

Publications (1)

Publication Number Publication Date
DK2742068T3 true DK2742068T3 (da) 2019-06-11

Family

ID=46679261

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12747915.2T DK2742068T3 (da) 2011-08-09 2012-08-08 Nye antistoffer mod phosphorylcholin

Country Status (28)

Country Link
US (3) US9803028B2 (enExample)
EP (1) EP2742068B1 (enExample)
JP (1) JP6277125B2 (enExample)
KR (1) KR101947758B1 (enExample)
CN (1) CN104039832B (enExample)
AR (1) AR087485A1 (enExample)
AU (1) AU2012293646B2 (enExample)
BR (1) BR112014002929A8 (enExample)
CA (1) CA2843921A1 (enExample)
CY (1) CY1121950T1 (enExample)
DK (1) DK2742068T3 (enExample)
ES (1) ES2732838T3 (enExample)
HK (1) HK1200852A1 (enExample)
HR (1) HRP20190988T1 (enExample)
HU (1) HUE045163T2 (enExample)
LT (1) LT2742068T (enExample)
MX (1) MX364425B (enExample)
PL (1) PL2742068T3 (enExample)
PT (1) PT2742068T (enExample)
RS (1) RS58986B1 (enExample)
RU (1) RU2654584C2 (enExample)
SG (1) SG2014009344A (enExample)
SI (1) SI2742068T1 (enExample)
SM (1) SMT201900366T1 (enExample)
TR (1) TR201909072T4 (enExample)
TW (1) TWI707873B (enExample)
WO (1) WO2013020995A1 (enExample)
ZA (1) ZA201400665B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012294431B2 (en) 2011-08-09 2017-03-30 Athera Biotechnologies Ab Antibodies binding to phosphorylcholine (PC) and/or PC conjugates
SI2742068T1 (sl) * 2011-08-09 2019-08-30 Athera Biotechnologies Ab Nova protitelesa proti fosforilholinu
US10942184B2 (en) 2012-10-23 2021-03-09 Caris Science, Inc. Aptamers and uses thereof
US20180066262A1 (en) 2015-03-09 2018-03-08 Caris Science, Inc. Oligonucleotide probes and uses thereof
EP3314027A4 (en) 2015-06-29 2019-07-03 Caris Science, Inc. THERAPEUTIC OLIGONUCLEOTIDES
EP3328873B1 (en) 2015-07-28 2025-09-17 Caris Science, Inc. Targeted oligonucleotides
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2402664A1 (fr) 1977-09-07 1979-04-06 Agronomique Inst Nat Rech Produits de couplage phosphorylcholine, composes amines procede d'obtention et applications
US5955584A (en) 1986-03-31 1999-09-21 Charter Ventures Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
DE3751182T2 (de) 1986-08-06 1995-10-26 Scripps Clinic Res Monoklonale Antikörper, B-spezifisch für Apolipoprotein, die von zwei Hybridomen erzeugt werden.
JPH02188532A (ja) 1989-01-17 1990-07-24 Otsuka Pharmaceut Co Ltd リポソームワクチン
WO1990012632A1 (en) 1989-04-19 1990-11-01 The United States Of America, Represented By The Secretary, United States Department Of Commerce Process for removing c-reactive protein and anti-phosphorylcholine antibodies from biological fluids
JP3283041B2 (ja) 1990-07-13 2002-05-20 学校法人藤田学園 人工抗体
EP0562020A4 (en) 1990-12-10 1993-11-18 Alving, Carl L. A vaccine against cholesterol to prevent hypercholesterolemia and atherosclerosis
RU2014609C1 (ru) * 1991-06-06 1994-06-15 Московский институт тонкой химической технологии им.М.В.Ломоносова Способ определения белков, специфичных к фосфорилхолину
EP0631624A1 (en) 1992-03-03 1995-01-04 The Rockefeller University Receptor complexes with b29 (ig-beta or ig-gamma) and their uses
AU5959494A (en) 1992-12-29 1994-07-19 Entremed, Inc Vaccines against sterols
AU6268894A (en) 1993-02-22 1994-09-14 Alza Corporation Compositions for oral delivery of active agents
US5455032A (en) 1993-07-29 1995-10-03 The United States Of America As Represented By The Department Of Health And Human Services Use of phosphocholine hapten conjugates in vaccines
AU1159497A (en) 1996-11-08 1998-06-03 Regents Of The University Of California, The Methods and reagents for non-invasive imaging of atherosclerotic plaque
US6375925B1 (en) 1996-11-08 2002-04-23 The Regents Of The University Of California Methods and reagents for non-invasive imaging of atherosclerotic plaque
US6225070B1 (en) 1997-08-07 2001-05-01 The Regents Of The University Of California Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma
US20040185039A1 (en) 2002-08-30 2004-09-23 Heinz Kohler Therapeutic applications of noncovalent dimerizing antibodies
US6300308B1 (en) 1997-12-31 2001-10-09 Board Of Regents, The University Of Texas System Methods and compositions for inducing autoimmunity in the treatment of cancers
SE9802402D0 (sv) 1998-07-03 1998-07-03 Karolinska Innovations Ab Method of diagnosing cardiovascular disease and early atherosclerosis
ES2205853T3 (es) 1998-07-03 2004-05-01 Athera Biotechnologies Ab Metodo para diagnosticar la enfermedad cardiovascular y la aterosclerosis precoz.
JP2003513027A (ja) 1999-10-26 2003-04-08 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア アテローム性動脈硬化症の診断、結像、治療用の薬剤及びその方法
SE0000855D0 (sv) 2000-03-15 2000-03-15 Karolinska Innovations Ab Antigenic composition useful as a vaccine against atherosclerosis
AU2001259730A1 (en) 2000-05-12 2001-11-26 The Regents Of The University Of California Standardized oxidized ldl assay
DE10041515A1 (de) 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
SE0103754L (sv) 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
US20070122419A1 (en) 2003-04-11 2007-05-31 The Regents Of The University Of California Methods and compositions for treating atherosclerosis
CN1968965B (zh) 2004-04-15 2015-12-16 阿瑟拉生物技术公司 磷酸胆碱偶联物和相应抗体
JP2008515774A (ja) 2004-08-03 2008-05-15 ダイアックス コーポレイション hK1結合タンパク質
WO2006110831A2 (en) 2005-04-12 2006-10-19 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
US20080311122A1 (en) 2005-11-28 2008-12-18 Medimmune, Llc Antagonists of Hmgb1 and/or Rage and Methods of Use Thereof
US20090258005A1 (en) 2007-05-29 2009-10-15 Trubion Pharmaceuticals Inc. Therapeutic compositions and methods
JP5122908B2 (ja) 2007-10-17 2013-01-16 日泉化学株式会社 自動車の内装用部材の取り付け構造
US20110206679A1 (en) * 2008-07-07 2011-08-25 Athera Biotechnologies Ab New Therapeutic and Diagnostic Methods for Alzheimer's Disease
WO2012010291A1 (en) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for metabolic disease
KR102502293B1 (ko) * 2011-01-06 2023-02-21 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
SI2742068T1 (sl) * 2011-08-09 2019-08-30 Athera Biotechnologies Ab Nova protitelesa proti fosforilholinu
AU2012294431B2 (en) 2011-08-09 2017-03-30 Athera Biotechnologies Ab Antibodies binding to phosphorylcholine (PC) and/or PC conjugates

Also Published As

Publication number Publication date
MX2014001313A (es) 2014-07-28
PL2742068T3 (pl) 2020-01-31
LT2742068T (lt) 2019-07-10
US20140178410A1 (en) 2014-06-26
WO2013020995A1 (en) 2013-02-14
JP2014525233A (ja) 2014-09-29
CN104039832A (zh) 2014-09-10
AU2012293646B2 (en) 2017-08-31
SI2742068T1 (sl) 2019-08-30
HK1200852A1 (en) 2015-08-14
US20210238311A1 (en) 2021-08-05
US9803028B2 (en) 2017-10-31
HRP20190988T1 (hr) 2019-09-20
CN104039832B (zh) 2021-02-12
ZA201400665B (en) 2019-08-28
TWI707873B (zh) 2020-10-21
SMT201900366T1 (it) 2019-07-11
PT2742068T (pt) 2019-07-08
ES2732838T3 (es) 2019-11-26
EP2742068B1 (en) 2019-04-03
HUE045163T2 (hu) 2019-12-30
AR087485A1 (es) 2014-03-26
CY1121950T1 (el) 2020-10-14
AU2012293646A1 (en) 2014-02-20
TW201321415A (zh) 2013-06-01
SG2014009344A (en) 2014-07-30
AU2012293646A8 (en) 2014-03-06
RU2014108815A (ru) 2015-09-20
BR112014002929A8 (pt) 2021-09-28
KR101947758B1 (ko) 2019-02-14
KR20140068948A (ko) 2014-06-09
MX364425B (es) 2019-04-25
BR112014002929A2 (pt) 2017-03-28
US20180086848A1 (en) 2018-03-29
EP2742068A1 (en) 2014-06-18
TR201909072T4 (tr) 2019-08-21
RU2654584C2 (ru) 2018-05-21
JP6277125B2 (ja) 2018-02-07
RS58986B1 (sr) 2019-08-30
CA2843921A1 (en) 2013-02-14

Similar Documents

Publication Publication Date Title
HUS2300021I1 (hu) Anti-IL-36R antitestek
DE112012003620T8 (de) Kartusche
LT2751083T (lt) Kvinolono junginys
DK2744810T4 (da) Tenofovir-alafenamid-hemifumarat
DK2769050T3 (da) Propsensor
DE102011100082A8 (de) Traygreifvorrichtung
BR112014012016A2 (pt) compostos
CO6910197A2 (es) Compuestos novedosos
BR112014000879A2 (pt) deflegmador
EP2729605A4 (en) RNA YY1 INTERACTIONS
DK3272861T3 (da) Alpha-galactosidase-sammensætninger
EP2701512A4 (en) Aldosterone synthase inhibitors
CO6960543A2 (es) 2-tiopirimidinonas
BR112013028029A2 (pt) composto
DK3141251T3 (da) Koloskopi - forberedelse
DK2742068T3 (da) Nye antistoffer mod phosphorylcholin
EP2708561A4 (en) BIO-PIN
EP2654196A4 (en) CONVERTER
DE112011104936A5 (de) Stanzstauchniet
CO6841994A2 (es) Anticuerpos
DE112012000958A5 (de) Handsäge
EP2775735A4 (en) ULTRASONIC SENSOR
BR112014015607A2 (pt) composto
BR112013032866A2 (pt) composto
EP2698098A4 (en) campimeter